enicepatide vs RAY1225

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

enicepatide

Developed by Roche and partners

Phase 3 in Obesitypeptide
Reliable signal

NCT06525935 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled Phase 2 trial in 469 adults with obesity and at least one weight-related condition. Enicepatide 24 mg produced significantly greater weight loss than placebo at week 48, 22.5% placebo-adjusted by one analysis method and 18.3% by another, both p<0.001, meeting the trial primary comparison.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2027 · NCT07589686 (registry estimate)

Reported efficacy

Percent Change in Body Weight from Baseline to Week 48: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) (met)

Result source: NCT06525935

RAY1225

Developed by Guangdong Raynovent Biotech and partners

Phase 3 in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointenicepatideRAY1225
Body weight, % change—Trial running · NCT07670416—Trial running · NCT06893016
Weight loss of 5% or more—Trial running · NCT07670416—Trial running · NCT06893016
Weight loss of 10% or more—Trial running · NCT07670416—Trial running · NCT06893016
Waist circumference, change (cm)—Trial running · NCT07670416—Trial running · NCT06893016

Body weight, % change

enicepatide
—Trial running · NCT07670416
RAY1225
—Trial running · NCT06893016

Weight loss of 5% or more

enicepatide
—Trial running · NCT07670416
RAY1225
—Trial running · NCT06893016

Weight loss of 10% or more

enicepatide
—Trial running · NCT07670416
RAY1225
—Trial running · NCT06893016

Waist circumference, change (cm)

enicepatide
—Trial running · NCT07670416
RAY1225
—Trial running · NCT06893016
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

RAY1225: no structured comparison results are available for Obesity.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

enicepatide
Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) NCT06525935 · Phase 2 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: enicepatide's landscape · RAY1225's landscape